Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

Fig. 3

Relationship between serum concentrations of biomarkers at baseline and the efficacy of pirfenidone on progression-free survival. All patients were dichotomized by the median concentration of a SP-D, b SP-A and c KL-6 at baseline to the high and low biomarker subgroups. Blue lines, pirfenidone; black lines, placebo. The disease progression was defined by a > 10% relative decline in vital capacity from baseline and/or death. Progression-free survival was estimated using the Kaplan–Meier method and compared using the log-rank test

Back to article page